A Metaanalysis of Clinical Trials Comparing Moclobemide with Selective Serotonin Reuptake Inhibitors for the Treatment of Major Depressive Disorder

By Papakostas, George I.; Fava, Maurizio | Canadian Journal of Psychiatry, October 2006 | Go to article overview

A Metaanalysis of Clinical Trials Comparing Moclobemide with Selective Serotonin Reuptake Inhibitors for the Treatment of Major Depressive Disorder


Papakostas, George I., Fava, Maurizio, Canadian Journal of Psychiatry


Objective: To compare response rates among patients with major depressive disorder (MDD) treated with either moclobemide, an antidepressant thought to simultaneously enhance both noradrenergic and serotonergic neurotransmission, or selective serotonin reuptake inhibitors (SSRIs).

Methods: Using a random-effects model, we combined 12 trials involving 1207 outpatients with MDD.

Results: Patients treated with moclobemide were as likely to experience clinical response as those treated with SSRIs (risk ratio 1.08; 95% confidence interval, 0.92 to 1.26; P = 0.314). Simply pooling response rates for the 2 agents resulted in a 62.1% response rate for moclobemide and a 57.5% response rate for the SSRIs. A metaregression did not reveal a statistically significant relation between the mean moclobemide dosage for each study and the risk ratio for response rates. Further, we found no difference between the 2 treatments in overall discontinuation rates, discontinuation rates due to adverse events, or discontinuation rates due to lack of efficacy. Also, rates of fatigue or somnolence and of insomnia were similar between the 2 treatment groups. However, SSRI treatment was associated with higher rates of nausea, headaches, and treatment-emergent anxiety than was treatment with moclobemide.

Conclusions: These results suggest that moclobemide and the SSRIs do differ with respect to their side effect profiles but not in their overall efficacy in the treatment of MDD.

(Can J Psychiatry 2006;51:783-790)

Information on funding and support and author affiliations appears at the end of the article.

Clinical Implications

* Decisions on whether to treat MDD with moclobemide or an SSRI cannot be based on overall differential efficacy.

* Decisions on whether to treat MDD with moclobemide or an SSRl cannot be based on overall differential tolerability.

* There appear to be differences in the side effect profiles of the 2 agents.

Limitations

* The absence of comparative studies involving citalopram and escitalopram precludes generalization to all SSRIs.

* The lack of placebo comparison groups means that no conclusion can be made about the assay sensitivity of these trials.

* There were no outcome data for the subset of patients with atypical depression.

Key Words: moclobemide, selective serotonin reuptake inhibitor, monoamine oxidase inhibitor, major depressive disorder

Abbreviations used in this article

CI confidence interval

HDRS Hamilton Depression Rating Scale

MADRS Montgomery-Asberg Depression Rating Scale

MDD major depressive disorder

RCT randomized clinical trial

RR risk ratio

SSRI selective serotonin reuptake inhibitor

The serendipitous discovery of the precursors of 2 of the major contemporary antidepressant families during the late 1950s-iproniazid for the monoamine oxidase inhibitors and imipramine for the tricyclic antidepressants-has led to the subsequent development of numerous antidepressant compounds (1). Unfortunately, many depression patients continue to remain symptomatic despite several treatments (2,3). Until recently, known differences among available antidepressants were generally limited to aspects of safety and tolerability (1). However, over the past few years, several studies have suggested that treatment with antidepressants simultaneously enhancing noradrenergic and serotonergic neurotransmission, including venlafaxine (4), duloxetine (5), and the tricyclic antidepressant clomipramine (6,7), may result in higher response or remission rates than treatment with antidepressants that selectively enhance serotonergic neurotransmission.

Similar to clomipramine, venlafaxine, and duloxetine, the antidepressant moclobemide also simultaneously enhances serotonergic and noradrenergic neurotransmission (1). Specifically, moclobemide is a selective and reversible inhibitor of the monoamine oxidase-A isoenzyme (1) and is approved for the treatment of depression in Europe, Canada, and Australia. …

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Default project is now your active project.
Project items

Items saved from this article

This article has been saved
Highlights (0)
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

Citations (0)
Some of your citations are legacy items.

Any citation created before July 30, 2012 will labeled as a “Cited page.” New citations will be saved as cited passages, pages or articles.

We also added the ability to view new citations from your projects or the book or article where you created them.

Notes (0)
Bookmarks (0)

You have no saved items from this article

Project items include:
  • Saved book/article
  • Highlights
  • Quotes/citations
  • Notes
  • Bookmarks
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited article

A Metaanalysis of Clinical Trials Comparing Moclobemide with Selective Serotonin Reuptake Inhibitors for the Treatment of Major Depressive Disorder
Settings

Settings

Typeface
Text size Smaller Larger Reset View mode
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Full screen

matching results for page

Cited passage

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited passage

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.